ClinicalTrials.gg
RecruitingNCT04112927Updated Sep 30, 2026

Acoustic OSA Prediction During Wakefulness and Monitoring During Sleep

An observational study in Obstructive Sleep Apnea, sponsored by University of Manitoba. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by University of Manitoba · Observational

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.
Updated Sep 30, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
250
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 133 studies in Sleep Apnea, Obstructive with a site in Canada — 22 open to participants now, 31 under way, 4 of them phase 3. Sleep Apnea, Obstructive · Canada.

Planned enrollment
7th of 31
250 · median 100
Started
2021
with 6 others
Observational
31 of 133
8 open now
Primary completion
2028-09
later than 23 of 30 live
Registered
91st of 133
by date

Among the 133 studies in Sleep Apnea, Obstructive with a site in Canada, this one is the 7th largest by planned enrollment of the 31 observational ones that give a count, is one of 7 that started in 2021, is one of 31 observational ones, reaches primary completion later than 23 of the 30 other live ones, and was the 91st registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

22 of the 133 studies in Sleep Apnea, Obstructive with a site in Canada are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sleep Apnea, Obstructive with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the feasibility of sound analysis for: a) sleep apnea detection both during wakefulness and sleep, and b) flow-sound relationship during both wakefulness and sleep in patients and control individuals. The ultimate goal of our research is to simplify the current assessments for sleep apnea detection so that it is more convenient for patients and also much faster than the current techniques.

Read the detailed description

Sleep apnea, in particular obstructive sleep apnea (OSA), is one of the most common breathing disorders and is associated with major comorbidities such as higher risk perioperative complications. This is particularly concerning given that about 40-80% of people with moderate-severe OSA remain undiagnosed. Due to the resource-intensive assessments required to diagnose OSA and the significantly increased risk of car accidents and perioperative complications associated with undiagnosed OSA, there is a critical need to develop a more effective method to screen for OSA quickly and reliably.

The most widely used clinical OSA screening tool is the STOP-Bang questionnaire, which is a quick and easy-to-implement inquiry form that has a high sensitivity to detect moderate and severe OSA (>93%), but it has a very high rate of false positives (>63%). Thus, a significant number of patients without OSA will continue to be referred for PSG, which contributes to a strain on the healthcare system. Therefore, a quick and reliable screening tool for OSA and its severity during wakefulness is very appealing but challenging, as people with OSA do not show any apparent symptoms during wakefulness.

We have developed a novel screening algorithm for OSA based on the analysis of tracheal breathing sounds recorded from an individual during wakefulness, called AWakeOSA. It can predict OSA with a sensitivity (86%) similar to STOP-Bang, but with a much higher specificity (84%) for detecting individuals without OSA. The AWakeOSA technology still needs significant research and quality improvements to become a reliable home-care device for screening under unsupervised conditions, which is the central purpose of this project. In addition, we are interested to investigate the breathing sound changes from wakefulness to sleep in both groups of healthy and apneic population. For that, we need to record PSG data and breathing sounds during sleep in addition to recording breathing sounds during wakefulness.

We have also designed a specialized hardware device, called ASAD-3, capable of recording breathing sounds with high quality during both wakefulness (short-period recording) and during sleep (long hours recording) that uses two small microphones that are placed in contact with the skin over the trachea and lung, respectively. The hardware device will be utilized to optimize the AWakeOSA algorithm and work towards achieving a reliable home-care device for screening under unsupervised conditions.

The proposed technology will enable a reliable and quick diagnosis of OSA that can be either used in a clinician's office during wakefulness and/or used at home by people to monitor their own OSA. The outcomes of this study will benefit the health care system and society significantly as it will: 1) reduce the financial burden of OSA on the healthcare system by reducing the need for PSG and unnecessary preoperative resources; and 2) provide a quick and reliable personal OSA home-care monitoring system for better OSA treatment management.

03

Conditions studied

  • Obstructive Sleep Apnea

Keywords

  • Obstructive Sleep Apnea
  • OSA
  • Respiratory Sound Analysis
  • AwakeOSA
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

OSA Participants of this study will be anyone regardless of their sex, gender or ethnic background, who are suspected of OSA and meet the inclusion/exclusion criteria. In addition, we will record up to 50 healthy controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) age between 18 to 70 years.
  • 2) suspected of OSA and referred to full PSG study by a doctor.

Exclusion criteria

Exclusion Criteria:

  • 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders.
  • 2) having insomnia or restless leg.
  • 3) drug addiction.
  • 4) under the current, direct supervision of the PI of this study.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • OSA Participants

    Inclusion Criteria: 1) age between 18 to 70 years; 2) suspected of OSA and referred to full PSG study by a doctor. Exclusion Criteria: 1) being diagnosed with a chronic respiratory disease including pulmonary fibrosis, emphysema, respiratory infectious disease, nocturnal asthma, obstructive pulmonary lung disease, pulmonary hypertension, congestive heart failure, sleep related hypoventilation and neuromuscular disorders; 2) having insomnia or restless leg; 3) drug addiction; and 4) under the current, direct supervision of the PI of this study.

  • Healthy Controls

    Inclusion Criteria: 1) age between 18 to 70 years; 2) non-snorer, and being free of any sleep disorders. Exclusion Criteria: same as the OSA Participants. All participants must not have any cold or any other respiratory illness at the time of recording. Illiterate participants may still participate in the study; however, there must be a witness who is not involved in the study (i.e. PI, Co-PI, study coordinator, research assistants (RA)/students, etc.) present to witness the consent process between the participant and the individual obtaining consent.

06

What researchers measure

Primary outcomes

  1. OSA Severity

    Data recorded during wakefulness will be analyzed using our published AWakeOSA algorithm to classify the participants into two groups of those who have AHI below and above 15. We will also run Multivariate statistical analysis to find the main effect of OSA severity (AHI) on the sound features and their interaction with the anthropometric information.

    Time frame: 1 Day

Secondary outcomes

  1. Acoustic AHI correlation to PSG

    For the sleep data, we will find the correlation of the AHI values estimated by our acoustic device using our previous algorithm compared to those of the Polysomnogram (PSG).

    Time frame: 1 Day

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2021 (actual). Primary completion is estimated for Sep 2028, 83 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2023 → Sep 2028 and completion Dec 2024 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2019
First posted
Oct 2, 2019
StartActual
Oct 1, 2021
Primary completionEst.
Sep 1, 2028was Dec 2023
CompletionEst.
Dec 23, 2028was Dec 2024
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Sep 30, 2026
Sites
University of Manitoba is now Recruiting
Sep 30, 2026
Primary completion
Dec 1, 2023→Sep 1, 2028
Sep 30, 2026
Study completion
Dec 23, 2024→Dec 23, 2028
Sep 30, 2026
Contact
Study contact now listed: added a•••@gmail.com · •••7023; added z•••@umanitoba.ca · •••7023. See the current contact
Sep 30, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Manitoba · Winnipeg, CanadaContact added a•••@gmail.com · •••7023Contact added z•••@umanitoba.ca
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Active, not recruiting→Recruiting
    University of Manitoba is now Recruiting
    Primary completion Dec 1, 2023→Sep 1, 2028
    Study completion Dec 23, 2024→Dec 23, 2028
    Contact Study contact now listed: added a•••@gmail.com · •••7023; added z•••@umanitoba.ca · •••7023. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Manitoba · Winnipeg, CanadaContact added a•••@gmail.com · •••7023Contact added z•••@umanitoba.ca
    + 3 other changes: verification date, criteria formatting and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04112927
Responsible party
Sponsor
First posted
Oct 2, 2019
Start date
Oct 1, 2021
Primary completion
Sep 1, 2028 (estimated)
Completion
Dec 23, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Abnoor Kaur, M.Sc.
Contact
abnoorkaur9@gmail.com
2044747023
Zahra Moussavi, Ph.D.
Contact
zahra.moussavi@umanitoba.ca
2044747023
Zahra Kazem-Moussavi, Ph.D.
principal investigator · University of Manitoba

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion